Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

To assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing relapsing multiple sclerosis (RMS)

  • 0 views
  • 23 Mar, 2022
  • 10 locations
Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

The purpose of this study is to assess the efficacy of autologous PBSCT versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) for inflammatory MS failing alternate approved therapy. Disease progression, defined as a 1-point increase in the Expanded Disability Status scale (EDSS) on …

glatiramer acetate
mitoxantrone
natalizumab
dimethyl fumarate
tecfidera
  • 120 views
  • 08 Nov, 2020
  • 1 location
The Gilenya Pregnancy Registry

The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the

fingolimod
gilenya
  • 679 views
  • 18 May, 2022
  • 60 locations
COVID Vaccine Response in MS

The primary goal of this study is to assess the impact of the two major disease modifying therapy (DMT) classes (B cell therapies and S1P modulators) on humoral and cell-mediated immunity to SARS- CoV-2 vaccination compared to non-MS controls. We have chosen to compare DMT-treated MS patients to non-MS controls …

Accepts healthy volunteers
disease or disorder
fingolimod
gilenya
ocrelizumab
  • 0 views
  • 07 Oct, 2021